Genetically Engineered Pig Liver Sustains Human for 171 Days: A Landmark in Xenotransplantation
(Updated December 7, 2023)
The global organ shortage continues to claim thousands of lives annually. Now, a groundbreaking study published in the Journal of Hepatology details the first successful auxiliary liver xenotransplant from a genetically modified pig into a living human, offering a potential pathway to address this critical need. The recipient survived for 171 days, demonstrating the feasibility of using modified porcine livers to perform essential metabolic and synthetic functions in humans - a significant step forward, despite ongoing challenges.
The Organ Shortage: A Global Crisis
The World Health Organization estimates that the demand for organs far outweighs the supply,leading to preventable deaths while patients wait for life-saving transplants. The situation is particularly acute in countries like China, where hundreds of thousands are diagnosed with liver failure each year, yet only a fraction - approximately 6,000 in 2022 – recieve a transplant. This disparity underscores the urgent need for alternative organ sources. Xenotransplantation, the transplantation of living cells, tissues or organs from one species to another, represents a promising, though complex, solution.
First-in-Human Pig Liver Graft: details of the Procedure
The recipient in this landmark case was a 71-year-old man suffering from hepatitis B-related cirrhosis and hepatocellular carcinoma. Due to the advanced stage of his illness, he was ineligible for traditional surgical tumor removal or a conventional human liver transplant.
Surgeons performed an auxiliary liver transplant using a graft derived from a Diannan miniature pig. This wasn’t just any pig; it was genetically engineered with ten targeted gene alterations. These modifications were crucial, designed to:
* Reduce Xenoantigens: Minimize the risk of immediate immune rejection by removing proteins that trigger a human immune response.
* Enhance Compatibility: Incorporate human transgenes to improve compatibility with the human immune and coagulation systems.
Initial Success & Subsequent Complications
In the first month post-transplant, the pig liver functioned remarkably well. It successfully produced bile, generated essential coagulation factors, and showed no immediate signs of hyperacute or acute rejection. However, on day 38, the patient developed xenotransplantation-associated thrombotic microangiopathy (xTMA).
xTMA is a serious complication linked to complement activation – a part of the immune system – and subsequent damage to the lining of blood vessels.The graft was removed at this point. Fortunately, treatment with the complement inhibitor eculizumab and plasma exchange successfully resolved the xTMA.
The patient unluckily experienced several episodes of upper gastrointestinal bleeding and ultimately died on day 171. While the outcome wasn’t a long-term success, the 171-day survival with a functioning pig liver represents a major achievement.
expert Reactions: A New Era for Hepatology?
The study has garnered significant attention from the medical community.
Beicheng Sun, MD, PhD, lead investigator and President of the First Affiliated Hospital of Anhui Medical University, emphasized the importance of the case: “This case proves that a genetically engineered pig liver can function in a human for an extended period. It is a pivotal step forward, demonstrating both the promise and the remaining hurdles, particularly regarding coagulation dysregulation and immune complications, that must be overcome.”
Heiner Wedemeyer, MD, Co-Editor of the Journal of Hepatology, hailed the report as a “landmark in hepatology.” He stated, “It shows that a genetically modified porcine liver can engraft and deliver key hepatic functions in a human recipient.Simultaneously occurring, it highlights the biological and ethical challenges that remain before such approaches can be translated into wider clinical use. Xenotransplantation may open completely new paths for patients with acute liver failure, acute-on-chronic liver failure, and hepatocellular carcinoma. A new era of transplant hepatology has started.”
Vlad Ratziu, MD, PhD, Editor in Chief of the Journal of Hepatology, underscored the journal’s commitment to publishing cutting-edge research: “The publication of this case reaffirms the Journal of Hepatology as the world’s leading liver journal. We are committed to presenting cutting-edge translational discoveries that redefine what is possible in hepatology.”
Challenges and Future Directions
While this study represents a monumental step forward, several challenges remain before xenotransplantation becomes a widespread clinical reality:
* Immune Rejection: Despite genetic modifications, the risk of immune rejection remains a significant hurdle. further refinement of gene editing techniques is needed to minimize immune responses.
* Coagulation Issues: The development of xTMA highlights the complexities of coagulation regulation between species. Strategies to prevent and manage these complications are
Related reading